return to news
  1. Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

Market News

Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

Abha Raverkar

3 min read | Updated on November 19, 2026, 14:07 IST

SUMMARY

Alkem Labs stated that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial, or other activities of the company.

Stock list

Alkem Labs shares

Alkem Laboratories has a total market capitalisation of ₹61,402.61 crore as of November 19, 2026, according to data on the NSE. | Image: Shutterstock

Alkem Labs share price: Shares of Alkem Laboratories declined by as much as 2.1% to hit an intraday low of ₹5,115 per unit on the National Stock Exchange (NSE) on Thursday, November 19, as the United States (US) Food and Drug Administration (FDA) issued a warning letter for its manufacturing facility located in Amaliya, Daman.
Open FREE Demat Account within minutes!
Join now

According to a regulatory filing, the warning letter was issued after the US FDA conducted an inspection at the company’s manufacturing facility in Amaliya, Daman, from April 20, 2026, to May 1, 2026.

At the time, the US FDA had classified the inspection status of the said facility as Official Action Indicated (OAI). An OAI means that FDA inspectors observed one or more significant violations during an inspection.

The drug manufacturer further said that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial or other activities of the company.

Recent update

On Tuesday, November 17, the company’s promoter-group family trust, Samprada & Nanhamati Singh Family Trust, sold 5.98 crore of Alkem Labs’ shares in a block deal transaction worth ₹301.9 crore.

The shares were bought by DSP Mutual Fund, Nippon India Mutual Fund, ICICI Prudential Mutual Fund and HDFC Mutual Fund for a trade price of ₹5,050 apiece.

Q2 results

Alkem Labs saw its consolidated net profit fall 14.4% year-on-year (YoY) to ₹667.1 crore in the July-September quarter of the 2026-27 financial year (Q2 FY27), compared with ₹779.11 crore in the corresponding quarter of the preceding fiscal year.

Its consolidated revenue from operations jumped 13.8% YoY to ₹4,552 crore during the quarter under review, as against ₹ 4,001 crore in the second quarter of the 2025-26 fiscal year (Q2 FY26).

Alkem Labs share performance

At around 1:57 PM, the stock was trading 1.48% lower at ₹5,145 per equity share.

While the scrip lost 3% in the past week, it gained 3% over the month. On a year-to-date (YTD) basis, it has fallen 6%.

The shares hit a 52-week high of ₹5,933.50 per unit on January 13, 2026, and touched a year’s low of ₹4,811 apiece on October 22, 2026.

Alkem Laboratories has a total market capitalisation of ₹61,402.61 crore as of November 19, 2026, according to data on the NSE.


Disclaimer: This article is purely for informational purposes and should not be considered investment advice from Upstox. Please consult with a financial advisor before making any investment decisions.

About The Author

Abha Raverkar
Abha Raverkar is a post-graduate in economics from Christ University, Bengaluru. She has a strong interest in the markets and loves to unravel the nitty-gritties of the latest happenings in the world of markets, business, and the economy.

Next Story

End of additional stories